Introducing Sigyn Therapy™, a multi-function blood purification technology designed to address both the cytokine storm* and the pathogen sources that fuel sepsis, the # 1 cause of hospital deaths.
In the United States, the annual financial burden to treat sepsis alone is estimated to be $24 billion.*
Beyond sepsis, Sigyn Therapy a candidate to address other unmet needs in global health. These include, but are not limited to emerging pandemic threats, hepatic encephalopathy, bridge to liver transplant, and community-acquired pneumonia (CAP), which is a leading cause of death among infectious diseases. CAP is also the leading cause of death in children under five years of age and the catalyst for approximately 50% of sepsis and septic shock cases.
Prior to establishing Sigyn Therapeutics, our co-founders played instrumental roles in the development of three different technologies that the United States Food and Drug Administration (FDA) has permitted for use to treat COVID-19 infected individuals.
Stay informed and receive company updates straight to your inbox.
